2021 SGO Virtual Annual Meeting Saturday March 20

Here are highlights from the Virtual #SGOmtg sessions I attended on Saturday March 20, 2021. 

The morning began with a wonderful get-together for Patient Advocates at a 9am session. I am so glad to see patient advocates play a role in so many aspects of the SGO organization.

 In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags

 Surgery:

Scientific Plenary II: Cutting Edge - Advancing Surgical Innovation -If Looks Could Kill: Morphologic Subtypes of High-Grade Serous Ovarian Cancer
Dr Katelyn Handley- Looking at morphology and molecular difference in OC #SGOMtg #gyncsm #SGOPatAdv pic.twitter.com/LavQt2RBLp

— Dee Sparacio (@womenofteal) March 20, 2021

Higher Surgical Volume is Associated with Better Outcomes for Frail Patients Undergoing Surgery for Ovarian Cancer- M. Nakhla #SGOMtg #gyncsm pic.twitter.com/3ZU7q8KZ0R

— Dee Sparacio (@womenofteal) March 20, 2021

MEDSCAPE shared this article on MIS and interval debulking surgery. https://www.medpagetoday.com/meetingcoverage/sgo/91738

Equity 

Education Forum V: Eradicating Racism and Discrimination in Medicine Thank you Dr Latimore. #SGOMtg #gyncsm
Have you ever taken a test to measure your implicit bias? I have. Results were not what I expected. We can do better. "See people as an individual." pic.twitter.com/bCEYQ1IDiY

— Dee Sparacio (@womenofteal) March 20, 2021

Education Forum V: Eradicating Racism and Discrimination in Medicine #SGOMtg #gyncsm
Dr Marsh
"We have to see it."
"Honesty is more important than fear"
We need to do this now. pic.twitter.com/48BS8u4I2B

— Dee Sparacio (@womenofteal) March 20, 2021

How to address our own biases? We needs to address our own biases while addressing bigger picture in our society! #SGOMtg #sgo2021 @SGO_org @somedocs #MedTwitter #obgyntwitter #gyninfluencer pic.twitter.com/Kk20tx51YD

— Payam Katebi Kashi, MD, PhD (@PayamKashiMD) March 20, 2021

PAOLA-1 Olaparib plus Bev

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
HR repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial
E. Pujade-Lauraine#SGOMtg #gyncsm pic.twitter.com/sEUkrDBAzJ

— Dee Sparacio (@womenofteal) March 20, 2021

Tumor infiltrating lymphocytes

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Great job @AmirJazaeri - impressive response of #cervicalcancer to TIL therapy with LN-145! Responses were durable and median duration of response was not reached. #SGOMtg #gyncsm pic.twitter.com/QDaLusnqv3

— Shannon Westin (@ShannonWestin) March 20, 2021

Keynote 158 Cervical Cancer

Updated data from the KEYNOTE-158 study of pembrolizumab in recurrent #cervicalcancer - response rate of 17% in pts with PD-L1 positive tumors. Median time to response was 2 months- fast acting! Med duration of response not reached... #SGOMtg #gyncsm pic.twitter.com/ut0EinNBvy

— Shannon Westin (@ShannonWestin) March 20, 2021

 

Scientific Plenary III: Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study
H. Chung#SGOmtg #gyncsm pic.twitter.com/qdBegPgXfZ

— Dee Sparacio (@womenofteal) March 20, 2021

 ENGOT-OV 16/ NOVA  niraparib

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Dr Matulonis
ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian #SGOmtg #gyncsm pic.twitter.com/wwd9DwuTho

— Dee Sparacio (@womenofteal) March 20, 2021

PARP Inhibitor duration of follow-up

Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials Bradley
Seminal Abstract Session: Taking a Deeper Dive into Practice-Changing Trials
Longest duration of follow -up of a PARP inhibitor in trials to date. #SGOmtg #gyncsm pic.twitter.com/hFNBwgsZ5K

— Dee Sparacio (@womenofteal) March 20, 2021

Cervical Cancer Radiation study

#SGOmtg
Translational Research 2021:
Genomic profiling of adv cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial #gyncsm
C. Lan
predictive Biomarker research for cervical cancer pic.twitter.com/IuoDprILOi

— Dee Sparacio (@womenofteal) March 20, 2021

Phase III Ran Trial of Postoperative Adjuvant Conventional Radiation (3DCRT) vs Image Guided Intensity Modulated Radiotherapy (IG-IMRT) in Cervical Cancer (PARCER)
S. Chopra
Reduction in diarrhea, #sgomtg#gyncsm pic.twitter.com/iGgp0EEcdF

— Dee Sparacio (@womenofteal) March 20, 2021

Shared Decision Making Tool

Niraparib as Maintenance Therapy- Dr Matalunis https://ascopost.com/videos/sgo-2021-virtual-annual-meeting-on-womens-cancer/ursula-matulonis-on-ovarian-cancer-niraparib-as-maintenance-therapy/

Priority Assessment for Women with Recurrent Ovarian Cancer: A Pilot Study presented by @StephanieVBlank Aids shared-decision making! Feasible with 97% completion! Next steps: Ongoing assessments, electronic version, languages #SGOmtg #SGOPatAdv #GYNcsm pic.twitter.com/hF4ntyzCwk

— Annie Ellis (@Stigetta) March 21, 2021

TY patients 4 insights Priorities Assessment Tool! Prior work https://t.co/O8UAvCtEKC https://t.co/COvGQgQJeN revealed needs-Standardized way 2 individualize tx discussions &capture changes tx goals/priorities along care continuum @MelissaFrey2 @StephanieVBlank #SGOmtg #SGOPatAdv pic.twitter.com/QDhiPDc8vs

— Annie Ellis (@Stigetta) March 21, 2021

Stop by tomorrow for my Sunday highlights.  

Dee

Every Day is a Blessing!

OC Awareness Month #8 -Treatments

Today I will review the treatment that a women diagnosed with ovarian cancer might receive. Of course every woman is different so your actual treatment might differ.

*A women diagnosed with ovarian cancer should see a  gynecologic oncologist ( gyn-onc) . Research has shown that women who receive surgery and treatment by a gyn-onc have higher survival rates.

There are different treatments offered to women diagnosed with ovarian cancer. Such as :

Surgery :
Hysterectomy- removal of the uterus and sometimes the cervix
Oopherectomy - removal of the ovaries and fallopian tubes
Oomectomey - removal of the oomentum the fatty covering of the abdomen
Lymph node biopsy-removal of lymph nodes which are examined for cancer

Chemotherapy:
Chemotherapy drugs disrupt the multiplication of cancer cells or kills them outright.The chemotherapy may be give IV, intravenously, where the drug is introduced into a vein or IP , intraperitoneal where the drug is introduced into the peritoneal cavity. Women may receive a combination of two drugs.

The most common drugs given to women with OC are carboplatin, cisplatin and paclitaxel. Additional drugs may be found on this NCI site http://www.cancer.gov/cancertopics/druginfo/ovariancancer.You might also receive targeted therapy , drugs or biologics. Targeted therapy will affect cancer cells but leave normal cells alone.

Radiation:
Radiation may be used to kill cancer cells in some cases of OC. The level depends on the type of OC cancer and stage of the disease.

 Source : http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page4


Tomorrow the stages of ovarian cancer

Dee
Every Day is a Blessing!